The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing held a virtual winter meeting and a hybrid summer meeting in 2022. Ad hoc working groups have several breakpoint revisions underway for multiple organism-drug combinations.
The US FDA has accepted a Biologics License Application (BLA) for Seres Therapeutics' SER-109, and set a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2023.
A multicenter, retrospective observational study looked at appropriate antibiotics for the treatment in this patient population.
Investigators examined the profiles of the HepB-CPG vaccine and HepB-alum vaccines to study the onset of select immune-mediated diseases, herpes zoster, or anaphylaxis.
A late-breaking IDWeek 2022 study found high seroprotection was achieved among people living with HIV after receiving 3 doses of a hepatitis B vaccine.
Using the DRIP Score along with newer diagnostic technology may determine the course of antibiotics for certain patients with pneumonia more efficiently and efficaciously.
Traditional therapy coverage does not include recent data that offers some updates in evaluating the current effectiveness of empiric antibiotic treatment.
A member of the Infectious Diseases Society of America (IDSA) leadership feels there is some inroads being made in Congress for this antimicrobial resistance legislation.
What makes Novavax’s COVID-19 booster different? The adjuvanted vaccine “has kept recognizing variants that arise,” says Novavax executive director Germán Áñez, MD.
Our cover story for the October 2022 print edition of Contagion details the original coronavirus.
After the Clinical and Laboratory Standards Institute (CLSI) revised their clinical breakpoints for susceptibility test results, a laboratory at a major medical center in a large midwest city evaluated enterobacterales as it relates to bloodstream infections (BSI) and piperacillin/tazobactam.
Late breaking data was reported utilizing the monoclonal antibody during the era of when Omicron variant was the predominant strain and demonstrated good outcomes and tolerability.
During a late breaking session at ID Week, an investigator presented data on the GSK vaccine that is in development.
Dr. Simon Portsmouth elaborates on the potential of Shionogi's cefiderocol, an up-and-coming agent in the fight against antimicrobial resistance.
Evidence on this has been conflicting and a poster presented at ID Week offers more insights on this significant topic.
The investigational vaccine was effective in reducing both lower respiratory tract and all respiratory tract infections.
After Helen Boucher, MD, gave the Maxwell Finland presentation she spoke of the continuing issues as well as the encouraging aspects that have institutions working on the problem.
There is a significant need for C difficile treatments that don’t destroy the microbiome.
Despite no significant reduction in time to discharge or recovery, inhalable SNG001 may lessen common symptoms of “long COVID.”
Breakthrough COVID-19 infections were rare in fully vaccinated individuals, but the average breakthrough occurred just under 50 days after complete vaccination.
At IDWeek 2022, antimicrobial stewardship was front and center. However, not all tests are created equal.
There is an evolution of thinking about how this is treated and investigational therapies are looking to help these patients improve not only their medical conditions but give them back their quality-of-life.
Evidence demonstrates how these therapies are prescribed around patients’ races.
The Novavax booster dose administered in a small study induced more robust antibody responses and its safety profile was considered favorable.
Antimicrobial stewardship works, one IDWeek 2022 study found.
A retrospective cohort study looked at the addition of utilizing a rapid test for gram-positive blood cultures and if time to diagnosis reduced vancomycin duration.
Distance to the clinic negatively impacted whether the HCV-positive individual attended their first HCV visit.
The phase 2, randomized, placebo-controlled, dose-finding trial evaluated the mRNA-based cytomegalovirus vaccine, which features a lipid nanoparticle formulation.
A Health-Related Quality of Life questionnaire designed to gather data on an investigational microbiota therapeutic demonstrated patients felt better about their conditions.
Shionogi shared positive clinical cure rates from their ongoing trial of Fetroja (cefiderocol) for difficult-to-treat Gram-negative infections.
